There has been interest in identifying other treatment options for patients with poorly differentiated neuroendocrine tumours (NETs) including CXCR4-targeted therapies as strong receptor expression on the tumour cell surface would pave the way for CXCR4-targeted radionuclide therapy in somatostatin receptor (SSTR)-negative patients, given the limited treatment options in de-differentiated NETs. The gene discussed is CXCR4; the disease is neoplasm.